Crinetics Pharmaceuticals (CRNX) Misses Q4 EPS by 4c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 EPS of ($0.90), $0.04 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $0 versus the consensus estimate of $197.1 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Limoneira sells vineyard property for $15M at public auction
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance